@conference{b84c3169482e44c0b53f2b0b5fca49dc,
title = "Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.",
author = "Norden, \{Andrew David\} and David Schiff and Ahluwalia, \{Manmeet Singh\} and Lesser, \{Glenn Jay\} and Lakshmi Nayak and Lee, \{Eudocia Quant\} and Alona Muzikansky and Jorg Dietrich and Smith, \{Katrina H.\} and Gaffey, \{Sarah C.\} and McCluskey, \{Christine Sceppa\} and Ligon, \{Keith L.\} and Reardon, \{David A.\} and Wen, \{Patrick Y.\}",
note = "TPS2104 Background: Bevacizumab is the standard of care for patients with recurrent high-grade glioma (HGG). However, with current treatment options the median duration of response is only approximately 4 months. Potential mechanisms of resistance include upregulation of fibroblast growth factor (FGF) and increased pericyte coverage mediated by platelet-derived growth factor (PDGF).; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2013",
month = may,
day = "20",
doi = "10.1200/JCO.2013.31.15\_SUPPL.TPS2104",
language = "American English",
}